Profile Technologies (PRTK) Narrows Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results
November 12, 2015 7:01 AM ESTEnrolling Patients in Phase 3 Registration Study of Omadacycline in Community Acquired Bacterial Pneumonia Granted FDA Fast Track Status for Omadacycline Advancing Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin Structure Infections According to Plan
BOSTON, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended September 30, 2015. This quarter the company reported a net loss attributable to common... More
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results
November 12, 2015 7:00 AM ESTEnrolling Patients in Phase 3 Registration Study of Omadacycline in Community Acquired Bacterial Pneumonia Granted FDA Fast Track Status for Omadacycline Advancing Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin Structure Infections According to Plan
BOSTON, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended September 30, 2015. This quarter the company reported a net loss attributable to common... More
